HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

NCT05348811 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: HAIC combined with donafenib and sintilimab

Sponsor

Zhongda Hospital